Table 3. Acute effects of esculentin-2CHa and its analogues on glucose tolerance and insulin release in high fat fed mice.

Peptide	Plasma glucose (AUC, mmol/l.min)	Plasma insulin (AUC, ng/ml.min)
Control	693.53±71.34	111.86±14.03
Esculentin-2CHa	463.99±46.95*	165.05±16.89*
[L21K]Esculentin-2CHa	598.68±35.23ΔΔ	131.12±14.25Δ
[L24K]Esculentin-2CHa	662.25±32.14ΔΔ	129.89±11.02Δ
[L28K]Esculentin-2CHa	327.61±36.87** , Δ	262.81±30.56** ,ΔΔΔ
[L31K]Esculentin-2CHa	410.72±29.25*	240.32±31.04** ,ΔΔΔ
[C31S, C37S]Esculentin-2CHa	618.65±86.0ΔΔ	122.74±28.65Δ
[D20K, D27K]Esculentin-2CHa	667.78±60.23ΔΔ	122.96±16.76Δ

Plasma glucose and insulin were measured prior to and after intraperitoneal administration of high fat fed mice with glucose (18 mmol/kg) alone (control) or in combination with peptide (75 nmol/kg body weight). Integrated responses to are presented as area under the curve values (AUC) for data collected at 0, 15, 30 and 60 min after peptide administration. Values are mean ± SEM with n = 8.

*P < 0.05

**P < 0.01 compared with control 5.6mM glucose. ^ΔP < 0.05, ^ΔΔP<0.01, ^ΔΔΔP<0.001 compared with mice injected with esculentin-2CHa.